anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Analyze Data

Slide function collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 58,039
Current window 17,551-17,580
Pages 1,935
Rows per page 30
Slide function: Analyze Dataclear collectionreset all
18 30 60

Slide function

17,551-17,580 of 58,039

filter-aware
05
The text highlights discrepancies in reported ESKD numbers between different sources and questions the statistical significance of the primary renal outcome.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The Monster1 hit
08
The slide argues that the drug Atrasentan acts as a 'band-aid' by masking symptoms via surrogate endpoints without providing long-term structural benefit.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
10
The slide provides a critical analysis of a standard medical metric, highlighting its inaccuracies and limitations in clinical practice.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
14
Includes references to clinical trial data and expert commentary regarding cardiovascular and renal side effects of atrasentan.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
16
The slide highlights discrepancies in reported clinical trial data, specifically regarding ESKD progression and adverse event reporting.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
18
The slide uses Kaplan-Meier survival curves to illustrate the effects of Atrasentan on primary composite renal outcomes in different patient cohorts.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
19
The slide argues that the drug causes fluid retention and anemia, contradicting the trial's stated conclusions.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
10
The slide uses a calculation table to demonstrate that shareholder loans are being repaid, contradicting S&P's view that they are permanent equity.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Monster1 hit
14
Includes footnotes 16-19 detailing calculation methodology and site visit observations.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The StruggleLoop · Iceberg1 hit
15
The table provides a granular view of property utilization, highlighting high vacancy rates in specific locations like Potsdamer Strasse.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The StruggleLoop · Iceberg1 hit
17
The slide presents property-specific due diligence findings regarding rent24's occupancy.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Struggle1 hit
18
The slide provides evidence for a short-selling thesis regarding undisclosed related party transactions and occupancy inflation.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Struggle1 hit
27
Includes three distinct tables detailing portfolio assets and financial performance.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory1 hit
35
The slide highlights a discrepancy in square footage to identify specific property assets (Potsdamer Straße 180, 182, and 184).Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory1 hit
36
The diagram illustrates complex cross-ownership between Vivion/Golden Capital Partners and various holding companies (Paxeal, Benelio, DME) leading to specific real estate assets in Germany.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory1 hit
39
The table shows a 4-month post spin-off period in 2019.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory1 hit
19
The table lists 12 entities across Cyprus and Germany with varying ownership stakes.Vivion Investments · Carson Block
Research note Short seller Beat · SolutionLoop · Cost Of Inaction1 hit
20
The slide is a page from a financial statement report, specifically Note 13 regarding investments.Vivion Investments · Carson Block
Research note Short seller Beat · SolutionLoop · Cost Of Inaction1 hit
21
The table compares Ecomondus 2018 financial statement reporting against individual Cyprus corporate records.Vivion Investments · Carson Block
Research note Short seller Beat · SolutionLoop · Cost Of Inaction1 hit
22
The document shows two share transfers of 50 shares each from Kklaw Nominees Limited and Cleserve Limited to Ecomondus Limited on 11/02/2019.Vivion Investments · Carson Block
Research note Short seller Beat · SolutionLoop · Cost Of Inaction1 hit
23
The document shows two share transfer entries to ECOMONDUS LIMITED, dated 11/02/2019.Vivion Investments · Carson Block
Research note Short seller Beat · SolutionLoop · Cost Of Inaction1 hit
24
Form shows transfer of 50 shares from KKLAW NOMINEES LIMITED and NDOLAN LTD to ECOMONDUS LIMITED on 11/02/2019.Vivion Investments · Carson Block
Research note Short seller Beat · SolutionLoop · Cost Of Inaction1 hit
25
Document shows share transfer from KKLaw Nominees Limited and Ndolan Ltd to Ecomondus Limited.Vivion Investments · Carson Block
Research note Short seller Beat · SolutionLoop · Cost Of Inaction1 hit
27
The document is a legal form for share transfer in a private company (Flekero Limited).Vivion Investments · Carson Block
Research note Short seller Beat · SolutionLoop · Cost Of Inaction1 hit
28
The slide serves as evidence to support the claim that there is no record of a share transfer to Ecomondus.Vivion Investments · Carson Block
Research note Short seller Beat · SolutionLoop · Cost Of Inaction1 hit
29
The slide serves as evidence that there is no record of a share transfer to Ecomondus in the official registry.Vivion Investments · Carson Block
Research note Short seller Beat · SolutionLoop · Cost Of Inaction1 hit
30
The slide highlights the absence of a share transfer record to Ecomondus in the official Cyprus Companies Section registry.Vivion Investments · Carson Block
Research note Short seller Beat · SolutionLoop · Cost Of Inaction1 hit
31
The slide serves as evidence for a lack of share transfer records.Vivion Investments · Carson Block
Research note Short seller Beat · SolutionLoop · Cost Of Inaction1 hit
32
Includes a red box annotation highlighting 'Afeciano Limited' as a new entity in 2019.Vivion Investments · Carson Block
Research note Short seller Beat · SolutionLoop · Cost Of Inaction1 hit
33
Includes a red box annotation highlighting Matanya Holdings Limited as the major creditor.Vivion Investments · Carson Block
Research note Short seller Beat · SolutionLoop · Cost Of Inaction1 hit